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LETTERS
Lethal 
Mycobacterium 
massiliense 
Sepsis, Italy 
To the Editor: A strain of My-
cobacterium massiliense was isolated 
from the blood of a kidney transplant 
patient in Italy at the same time she 
was diagnosed as having pulmonary 
tuberculosis.  M. massiliense bacter-
emia appears to have played a role in 
her sudden death.
The patient, a 63-year-old wom-
an who had had a kidney transplant 
10 years earlier and was receiving 
immunosuppressive treatment with 
cyclosporine, azathioprine, and pred-
nisolone, was hospitalized in an inten-
sive care unit because of septic shock, 
a stuporous condition, hypotension, 
respiratory insufﬁ   ciency, and acute 
renal failure. Results of initial micro-
biologic investigations (cultures of 
blood, urine, and bronchial aspirate, 
and nasal and pharyngeal swabs; tests 
for antigens of Legionella pneumophi-
la, pneumococcus, and Cryptococcus 
neoformans; and serologic analysis 
for pneumotropic viruses and bacte-
ria) were negative. 
Hematologic analysis showed 
leukopenia with high neutrophil 
counts. Septic shock–speciﬁ  c therapy 
was given along with wide-spectrum 
antimicrobial drug therapy (levoﬂ  oxa-
cin, trimethoprim-sulfamethoxazole, 
piperacillin-tazobactam, and ﬂ  ucon-
azole). After moderate improvement, 
the patient’s general condition wors-
ened and prompted a new round of mi-
crobiologic tests, including those for 
mycobacteria. After acid-fast bacilli 
were detected in a bronchial aspirate 
and results of nucleic acid ampliﬁ  ca-
tion (Amplicor; Roche, Basel, Swit-
zerland) were positive for M. tubercu-
losis complex, she was given standard 
antituberculosis treatment. She died 
the next day. 
Three blood cultures obtained 7 
days before the death of the patient 
showed positive results in aerobic bot-
tles but not in anaerobic bottles (BacT/
ALERT SA; bioMérieux, Marcy 
l’Etoile, France). Subcultures spread 
onto blood agar yielded small white 
colonies of gram-positive bacilli, in-
cluding branched forms, within 24 
hours. One month earlier, the patient 
had been seen as an outpatient with 
intermittent fever, and unidentiﬁ  ed 
gram-positive bacilli were observed in 
her blood culture.
Genetic sequencing of the ﬁ  rst 
one third of the 16S rDNA gene (1) 
of the strain (GenBank accession 
no. EU370523) showed 99.8% iden-
tity with M.  abscessus,  M.  bolletii, 
M. chelonae, and M. massiliense. To 
discriminate between these 4 species, 
a 723-bp fragment of the RNA poly-
merase β subunit (rpoB) gene (2) also 
was sequenced (GenBank accession 
no. EU370524). Sequencing showed 
100% similarity with M. massiliense; 
the next most closely related species 
was M. bolletii (98.6% similarity).
An isolate of M.  tuberculosis 
that was susceptible to all ﬁ  rst-line 
antituberculosis drugs was recovered 
from this patient’s bronchial aspirate 
in both solid and liquid media. Im-
munocompromised patients, includ-
ing those with organ transplants, are 
known to be prone to mycobacterial 
infections (3). Mixed mycobacterial 
infections also have been reported (4). 
This newly described species has been 
isolated from pulmonary ﬂ  uids  (5), 
blood (6), intramuscular injection sites 
(7), and surgical wounds (8). Because 
sequencing 16S rDNA does not differ-
entiate M. abscessus, M. bolletii, M. 
chelonae, and M. massiliense (5), use 
of the rpoB sequence is crucial.
As reported for isolates of M. 
massiliense ( 5–8), our isolate was 
characterized by high MICs (9) (broth 
microdilution by using the Sensititer 
RGMYCO; Trek Diagnostic Systems 
Inc., Cleveland, OH, USA) to most 
of the antimicrobial drugs tested. The 
isolate was sensitive only to clarithro-
mycin and amikacin and showed bor-
derline sensitivity to linezolid (Table).
Despite co-infection with M. tu-
berculosis, the patient’s death was 
likely caused by M. massiliense bac-
teremia. The patient died before the 
isolate was identiﬁ  ed as a mycobac-
terium, and unfortunately, none of 
the drugs used empirically was active 
against this organism.
Only speculations can be made 
about how this patient acquired the 
M. massiliense infection. However, 5 
months before her hospital admission, 
the patient had received a coxofemo-
ral arthroprosthesis as a result of a fall 
and had since complained of general-
ized bone pain and had remained bed-
ridden. Although in this case no proof 
exists, infection caused by rapidly 
growing mycobacteria after surgical 
intervention (10) is well known and 
should be considered.
M.  massiliense has been distin-
guished from M.  abscessus by se-
quencing of the rpoB gene (2). Be-
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Table. Antimicrobial drug resistance pattern of the strain of Mycobacterium massiliense 
isolated from the patient, Italy* 
Drug MIC (Pg/mL) Pattern
Amikacin 4 S
Amoxicillin/clavulanic acid  64/32 R
Cefoxitin 64 I
Ceftriaxone >64 R
Ciprofloxacin 16 R
Clarithromycin <0.12 S
Gatifloxacin >8 R
Imipenem 32 R
Linezolid 8 S
Tobramycin 16 R
Trimethoprim/sulfamethoxazole 8/152 R
*S, sensitive; R, resistant; I, intermediate resistance. LETTERS
cause this technology is available in 
relatively few clinical laboratories, 
cases of infection with M. massiliense 
may be mistakenly attributed to M. ab-
scessus. Although infections with M. 
massiliense may be underrecognized, 
reports of these infections are raising 
concern. The capacity of this bacteria 
to infect different body sites is further 
evidence for the pathogenic potential 
of a rapidly growing mycobacteria in 
human infections (10).
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Bovine Kobuviruses 
from Cattle with 
Diarrhea
To the Editor: A new species of 
kobuvirus, named U-1 strain, was ﬁ  rst 
recognized in 2003 as a cytopathic 
contaminant in a culture medium of 
HeLa cells that had been used for 
>30 years in the laboratory (1). The 
RNA genome of the U-1 strain com-
prises 8,374 nucleotides; the genome 
organization is analogous to that of 
picornaviruses. Morphologically, the 
U-1 strain resembles the Aichi virus, 
but genetically it is distinct (1). There-
fore, the U-1 strain is classiﬁ  ed as a 
new species of genus Kobuvirus in 
the family Picornaviridae, and it is 
called bovine kobuvirus (1). To date, 
the genus Kobuvirus consists of 2 spe-
cies, Aichi virus and bovine kobuvirus 
(2). The Aichi virus is associated with 
acute gastroenteritis in humans (3–5); 
bovine kobuvirus infection has been 
detected only in cattle (1).
Only 1 report has described the 
discovery and epidemiologic features 
of bovine kobuvirus (1). Of serum 
samples from 72 healthy cattle, 43 
(59.7%) were positive for neutralizing 
antibody against bovine kobuvirus U-1 
standard strain at a titer of >16. In ad-
dition, 12 (16.7%) of 72 stool samples 
collected from the cattle were positive 
for the bovine kobuvirus genome by 
reverse transcription–PCR (RT-PCR) 
(1). This ﬁ  nding suggested that bovine 
kobuvirus is common and that the vi-
rus particles could be detected in the 
stool samples of infected cattle. We 
therefore conducted an epidemiologic 
survey of bovine kobuvirus and report 
detection of this virus in stool sam-
ples from calves with diarrhea during 
2001–2004 in Chiang Mai Province, 
Thailand.
From November 2001 to July 
2004, a total of 72 fecal specimens 
were collected. The age of the calves 
ranged from 7 to 49 days. The pres-
ence of bovine kobuvirus in fecal 
specimens was detected by using RT-
PCR with a protocol modiﬁ  ed from 
the method described by Yamashita 
et al. (1). All the bovine kobuvirus 
strains detected in our study were 
analyzed further by direct sequenc-
ing of their PCR amplicons with the 
BigDye Terminator Cycle Sequencing 
Kit (Applied Biosystems, Foster City, 
CA, USA) on an automated sequencer 
(ABI 3100, Applied Biosystems). The 
nucleotide sequences of these portions 
were compared with those of refer-
ence strains available in the GenBank 
database by using BLAST (6). Phy-
logenetic and molecular evolutionary 
analyses were conducted by using 
MEGA version 3.1 (7). The nucleotide 
sequences of bovine kobuvirus strains 
described in this study were depos-
ited in GenBank under accession nos. 
EF659450–EF659455.
The bovine kobuvirus was detect-
ed by the RT-PCR screening method 
in 6 (8.3%) of the 72 fecal specimens 
collected. The partial 3D regions of all 
6 bovine kobuviruses exhibited highly 
conserved sequences of 99.3%–100% 
nucleotide and 100% amino acid 
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